

Remarks

Applicants thank the examiner for his valuable comments and have amended the claims as above. In view of these amendments, Applicants request withdrawal of the rejections in the Office Action dated September 18, 2008.

Claims 1-8, and 10-18 are pending with claim 1 being the only independent claim.

Rejection under 35 USC § 112


1. The Examiner has pointed out that the recitation of the term "free form ester and salt" makes the claim indefinite. Applicants have amended claim 1 to remove this term. Applicants believe that this amendment removes any indefiniteness.
2. The typographical error in Formula IV of claim 1, pointed out by the Examiner, has been corrected by replacing the carbon by a methyl group.
3. In claims 8 and 10, the plural term 'acids' has been replaced by the singular term 'acid'. Applicants believe that this removes any vagueness and lack of clarity in these claims.
4. In claim 3, the plural terms 'cyclohexanes' and 'heptanes' have been replaced by the singular 'cyclohexane' and 'heptane'. Applicants believe that these corrections remove any lack of clarity.
5. As noted above, claim 1 has been amended to remove the terms, lactone, ester and salt. Applicants believe that this amendment moots point No. 5 made by the examiner.

The Applicants would like point out that in doing the amendments, no matter has been added.

Conclusion

Applicants believe that the amendments mentioned above address and moot all rejection made by the examiner. Therefore, the Examiner is urged to pass claims 1-8 and 10-18 to issue. Authorization is hereby given to charge any fees or credits due in connection with this Response to Office Action to Deposit Account No. 50-0912.

Respectfully submitted,



---

George E. Heibel, PhD,  
Reg. No. 42, 648

Date: January 13, 2009

Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Tel: (609) 720-5334  
Fax: (609) 514-9779